Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Phase 2 Interventional

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

NCT04945772
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy Product-MCO-010, Sham Injection
Biological · Procedure
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 24, 2026, 9:17 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 24, 2026, 9:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients

NCT04700657
View directory record Official record
Conditions
Ocular GVHD
Interventions
corneal sensation test
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional Results available

Clinical Performance of a Silicone Hydrogel Contact Lens Following Six Nights of Extended Wear

NCT03614130
View directory record Official record
Conditions
Refractive Errors
Interventions
LID011121 contact lens, Comfilcon A contact lens
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Johns Creek, Georgia • Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 24, 2026, 9:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Novel Glaucoma Diagnostics

NCT00286637
View directory record Official record
Conditions
Glaucoma, Macular Disease
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional

Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients

NCT00454922
View directory record Official record
Conditions
Glaucoma
Interventions
standard of care, education
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cell Phone Application for Vision Assessment

NCT03212222
View directory record Official record
Conditions
Visual Impairment
Interventions
Peek Acuity, Standard Visual Screening
Other
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers

NCT00985231
View directory record Official record
Conditions
Vision Disorders
Interventions
PureVision Multi-Focal contact lenses, SofLens59 contact lens
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
30 Years to 40 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation

NCT00013429
View directory record Official record
Conditions
Blindness
Interventions
Visual
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional Results available

Beacon Sensors and Telerehabilitation for Low Vision

NCT04066075
View directory record Official record
Conditions
Low Vision
Interventions
Low Vision Rehabilitation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Fullerton, California • Grass Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression

NCT05713981
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Meibomian gland (MG) expression
Procedure
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old

NCT00315302
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 24, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

NCT02258854
View directory record Official record
Conditions
Uveitis
Interventions
Dose 2 gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
33
States / cities
Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

NCT03990051
View directory record Official record
Conditions
Chronic Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ topical gel, Placebo topical gel
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

NCT06131372
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Obesity
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
25
States / cities
Concord, California • Fresno, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Not applicable Interventional Results available

Performance Assessment of a Modified Daily Disposable Contact Lens

NCT03762668
View directory record Official record
Conditions
Refractive Errors, Myopia, Hyperopia
Interventions
Modified delefilcon A contact lenses, Delefilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Maitland, Florida • Orlando, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 24, 2026, 9:17 AM EDT
Recruiting Phase 3 Interventional

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

NCT05844982
View directory record Official record
Conditions
Radiation Retinopathy, Visual Impairment
Interventions
Faricimab, fluocinolone acetonide
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
29
States / cities
Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 9:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism

NCT04518059
View directory record Official record
Conditions
Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
punch skin biopsy
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years to 89 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 24, 2026, 9:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms

NCT00344838
View directory record Official record
Conditions
Customized Laser Ablation
Interventions
Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
458 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 24, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 24, 2026, 9:17 AM EDT
Not listed Not applicable Interventional

Transcorneal Electrical Stimulation (TES) for the Treatment of Amblyopia

NCT02495935
View directory record Official record
Conditions
Amblyopia
Interventions
OkuStim®, Sham-OkuStim®
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 24, 2026, 9:17 AM EDT